Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. announce the submission of a New Drug Application to the United States Food & Drug Administration for APP13007, a novel aqueous nanosuspension formulation of the potent corticosteroid, clobetasol propionate, for the treatment of inflammation and pain following ocular surgery.
